We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byDora McDowell
Modified about 1 year ago
Screening, Assessment and Management of Fatigue in Adult Survivors of Cancer: An American Society of Clinical Oncology Clinical Practice Guideline Adaptation © 2014 American Society of Clinical Oncology®. All rights reserved.
Introduction This guideline summarizes the results of a guideline adaptation process and presents recommendations on cancer-related fatigue Adapted from 3 existing guidelines: – Pan-Canadian guideline on Screening, Assessment and Care of Cancer-Related Fatigue in Adults with Cancer – NCCN Guideline for Cancer-Related Fatigue – NCCN Guideline for Surviorship © 2014 American Society of Clinical Oncology®. All rights reserved.
ASCO Survivorship Guidelines Growing number of cancer survivors ASCO has responded with steps to promote evidenced-based, comprehensive, compassionate, and coordinated survivorship care © 2014 American Society of Clinical Oncology®. All rights reserved.
Methods ASCO considers adaptation in selected circumstances – When one or more quality guidelines from other organizations already exist on the same topic ADAPTE Methodology – Take advantage of existing guidelines – Enhance efficiency and reduce duplication – Promote uptake of quality recommendations © 2014 American Society of Clinical Oncology®. All rights reserved.
Adaptation Process Literature search to identify candidate guidelines Methodological review Content review by an ad hoc, multidisciplinary Panel © 2014 American Society of Clinical Oncology®. All rights reserved.
Pan-Canadian and NCCN Guidelines All three guidelines offered comprehensive and user-friendly algorithms that were helpful in informing screening, assessment, and treatment options © 2014 American Society of Clinical Oncology®. All rights reserved.
Definition of cancer-related fatigue (Modified from NCCN Guidelines for Cancer-Related Fatigue and NCCN Guidelines for Survivorship) Cancer-related fatigue is a distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer and/or cancer treatment that is not proportional to recent activity and interferes with usual functioning. These guidelines are focused on fatigue in patients who have completed primary cancer treatment and/or are in clinical remission © 2014 American Society of Clinical Oncology®. All rights reserved.
Final Recommendations: Screening (Modified from Pan-Canadian and NCCN Guidelines for Cancer-Related Fatigue) All health care providers should routinely screen for the presence of fatigue from the point of diagnosis onward, including following completion of primary treatment. All patients should be screened for fatigue as clinically indicated and at least annually. Screening should be performed and documented using a quantitative or semi-quantitative assessment. © 2014 American Society of Clinical Oncology®. All rights reserved.
Final Recommendations: Comprehensive and Focused Assessment (Modified from NCCN Guidelines for Survivorship) History and Physical 1) Perform a focused fatigue history 2) Evaluate disease status 3) Assess treatable contributing factors As a shared responsibility, the clinical team must decide when referral to an appropriately trained professional (e.g., cardiologist, endocrinologist, mental health professional, internist, etc.) is needed. © 2014 American Society of Clinical Oncology®. All rights reserved.
Final Recommendations: Comprehensive and Focused Assessment Laboratory Evaluation (NCCN Guidelines for Survivorship verbatim) Consider performing laboratory evaluation based on presence of other symptoms, onset, and severity of fatigue o CBC with differential o Comprehensive metabolic panel o Endocrinologic evaluation © 2014 American Society of Clinical Oncology®. All rights reserved.
Final Recommendations: Treatment and Care Options Education and Counseling (Modified from Pan-Canadian and NCCN Guidelines for Cancer-Related Fatigue) All patients should be offered specific education about fatigue following treatment (e.g. information about the difference between normal and cancer- related fatigue, persistence of fatigue post treatment, and causes and contributing factors). Patients should be offered advice on general strategies that help manage fatigue (e.g., physical activity, guidance on self- monitoring of fatigue levels). If treated for fatigue, patients should be followed and re- evaluated on a regular basis to determine whether treatment is effective or needs to be reassessed. © 2014 American Society of Clinical Oncology®. All rights reserved.
Final Recommendations: Treatment and Care Options Treat Contributing Factors (Modified from Pan-Canadian and NCCN Guidelines for Survivorship) Address all medical and substance-induced treatable contributing factors first (e.g., comorbidities, medications, nutritional issues, activity level). Some patients can also benefit from interventions described in next slides to treat fatigue. Currently, there are no clear standards to select among these for an individual patient. Further research is needed to establish a strategy for prioritizing, sequencing, and linking the available options. © 2014 American Society of Clinical Oncology®. All rights reserved.
Final Recommendations: Treatment and Care Options Physical Activity (Modified from Pan-Canadian and NCCN Guidelines for Survivorship) Initiating/maintaining adequate levels of physical activity can reduce cancer-related fatigue in post-treatment survivors. Actively encourage all patients to engage in a moderate level of physical activity after cancer treatment (e.g., 150 minutes of moderate aerobic exercise such as fast walking, cycling, or swimming) per week with an additional 2 to 3 strength training (such as weight lifting) sessions per week, unless contraindicated. © 2014 American Society of Clinical Oncology®. All rights reserved.
Final Recommendations: Treatment and Care Options Walking programs are generally safe for most cancer survivors; the American College of Sports Medicine recommends that cancer survivors can begin this type of program after consulting with their doctors but without any formal exercise testing (such as a stress test). Survivors at higher risk of injury (e.g., those living with neuropathy, cardiomyopathy, or other long-term effects of therapy) and patients with severe fatigue interfering with function should be referred to a physical therapist or exercise specialist. Breast cancer survivors with lymphedema should also consider meeting with an exercise specialist before initiating upper body strength-training exercise. © 2014 American Society of Clinical Oncology®. All rights reserved.
Final Recommendations: Treatment and Care Options Psychosocial Interventions (Modified from NCCN Guidelines for Survivorship) Cognitive behavioral therapy/behavioral therapy can reduce cancer related fatigue in post-treatment survivors. Psycho-educational therapies/educational therapies can reduce cancer related fatigue in post-treatment survivors. Survivors should be referred to psychosocial service providers who specialize in cancer and are trained to deliver empirically-based interventions. Psychosocial resources that address fatigue may also be available through the National Cancer Institute and other organizations. © 2014 American Society of Clinical Oncology®. All rights reserved.
Final Recommendations: Treatment and Care Options Mind-body Interventions There is some evidence that mindfulness-based approaches, yoga, and acupuncture can reduce fatigue in cancer survivors. Additional research, particularly in the post-treatment population, is needed for biofield therapies (touch therapy), massage, music therapy, relaxation, reiki, and qigong. Survivors should be referred to practitioners who specialize in cancer and who use protocols that have been empirically validated in cancer survivors. © 2014 American Society of Clinical Oncology®. All rights reserved.
Final Recommendations: Treatment and Care Options Pharmacologic Interventions (Modified from NCCN Guidelines for Cancer-Related Fatigue and Survivorship) Evidence suggests that psychostimulants (e.g., methylphenidate) and other wakefulness agents (e.g., modafinil) can be effectively used to manage fatigue in patients with advanced disease or those on active treatment. However there is very limited evidence of their effectiveness in reducing fatigue in patients following active treatment who are currently disease-free. Small pilot studies have evaluated the impact of supplements, such as ginseng, vitamin D, and others for cancer-related fatigue. However, there is no consistent evidence of their effectiveness. © 2014 American Society of Clinical Oncology®. All rights reserved.
Final Recommendations: Treatment and Care Options Ongoing Monitoring and Follow-up Promote ongoing self-monitoring of fatigue levels, using a symptoms diary or other methods, as fatigue can be a late or long-term problem in post-treatment survivors. © 2014 American Society of Clinical Oncology®. All rights reserved.
Additional Resources Additional Information including data supplements, evidence tables, and clinical tools and resources can be found at Patient information is also available at © 2014 American Society of Clinical Oncology®. All rights reserved.
ASCO Panel Members Julienne E. Bower, Ph.D. (Co-chair) Psychology UCLA Departments of Psychology &Psychiatry/Biobehavioral Sciences Paul B. Jacobsen PhD (Co-chair) Psychology H. Lee Moffitt Cancer Center and Research Institute Ann Berger MSN, MD Pain and Palliative Care National Institutes of Health Clinical Center William Breitbart MD Psychiatry Memorial Sloan-Kettering Cancer Center Carmelita P. Escalante MD Internal Medicine University of Texas MD Anderson Cancer Center Patricia A. Ganz MD Medical Oncology University of California Los Angeles Schools of Medicine and Public Health Hester Hill Schnipper LICSW, BCD Patient Representative & Oncology Social Work Beth Israel Deaconess Medical Center Jennifer A. Ligibel MD Medical Oncology Dana-Farber Cancer Institute Gary H. Lyman MD,MPH, FASCO, FRCP Medical Oncology Duke University and the Duke Cancer Institute Mohammed S. Ogaily MD, FACP ASCO PGIN Representative, Medical Oncology Oakwood Center for Hematology and Oncology-Downriver William F. Pirl MD Psychiatry Massachusetts General Hospital © 2014 American Society of Clinical Oncology®. All rights reserved.
Disclaimer The information contained in, including but not limited to clinical practice guidelines and other guidance is based on the best available evidence at the time of creation and is provided by the American Society of Clinical Oncology, Inc. (“ASCO”) to assist providers in clinical decision making. The information should not be relied upon as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time information is developed and when it is published or read. The information is not continually updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular product or course of medical treatment. Further, the information is not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients. Recommendations reflect high, moderate or low confidence that the recommendation reflects the net effect of a given course of action. The use of words like “must,” “must not,” “should,” and “should not” indicate that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in certain cases. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. ASCO provides this information on an “as is” basis, and makes no warranty, express or implied, regarding the information. ASCO specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions. © 2014 American Society of Clinical Oncology®. All rights reserved.
©American Society of Clinical Oncology All rights reserved. Extended RAS Gene Mutation Testing in Metastatic.
Survivorship Essentials for Practice Administrators Christina Bach, MBE, MSW, LCSW, OSW-C Carolyn Vachani, MSN, RN, AOCN.
Lowell Smith Sr. Director, Business & Communication Research Administration Moffitt Cancer Center Jeanine Stiles Chief Administrative Officer Associate.
Are You Ready to Assess For Distress? Lee Tremback, MA, LCSW, OSW-C Oncology Social Worker Eastern Connecticut Cancer Institute John A. DeQuattro Cancer.
Mary S. McCabe Survivorship Care Planning. National Directions Focus on recurrence Increasing expectations by patients and families Identification of.
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
©American Society of Clinical Oncology All rights reserved. Adjuvant.
FOLLOW-UP CARE, SURVEILLANCE PROTOCOL, AND SECONDARY PREVENTION MEASURES FOR SURVIVORS OF COLORECTAL CANCER Clinical Practice Guideline Endorsement
A Clinician's Approach to Fatigue of Cancer Patients Jau-Yih Tsauo PT, PhD, Professor National Taiwan University.
Chapter 2 The Athletic Health Care Team Start today by taking out your notebooks. Brainstorm all of the people you think are part of the ATHLETIC HEALTH.
Cancer Program Standards 2012: Ensuring Patient- Centered Care Stephen Dreyer, MD, FACS October 22, 2014 CoC Surveyor Fremont Health Medical Center Fremont,
Supporting people in Dorset to lead healthier lives Commissioning the Dorset Community Persistent Pain Management Service Why is it so Painful to Commission.
Chapter 1: Sports Medicine: The Multidisciplinary Approach to Athletic Health Care.
File #1 Table of Contents Introduction Presenter’s Notes Oncology Rehabilitation: Web-based Learning for Physical Therapists Who Provide Rehabilitation.
Participation Requirements for a Guideline Panel PGIN Representative.
Grove House Services and Developments Sue Varvel – Director of Patients Services Fran Deane – Deputy Director of Patient Services.
Exercise Management Cancer. Pathophysiology Cancer is not a single disease; it is a collection of hundreds of diseases that share the common feature of.
Janice Berry Edwards, PhD, LICSW, LCSW-C, BCD, ACSW.
©American Society of Clinical Oncology All rights reserved. Reprinted.
The KU Wichita Center for Breast Cancer Survivorship Judy Johnston, MS, RD/LD Research Instructor Department of Preventive Medicine and Public Health,
Basma Y. Kentab MSc.. Define clinical pharmacy Differentiate between pharmacy and clinical pharmacy. Explain the qualification required for clinical.
American Society of Clinical Oncology Endorsement of the Cancer Care Ontario (CCO) Practice Guideline on Adjuvant Ovarian Ablation (OA) in the Treatment.
Unit 6.4: Tips for Successful Clinical Decision Support Systems Decision Support for Quality Improvement Component 12/ Unit 6.41Health IT Workforce Curriculum.
OCCUPATIONAL HEALTH NURSING. RULE 1070: OCCUPATIONAL HEALTH AND ENVIRONMENTAL CONTROL The member of the technical committee shall either be a physician,
ResultsIntroduction Atrial Fibrillation (AF) affects 1.2% 1 of the population and 10% of those over the age of 75 2 It is the commonest arrhythmia in primary.
Introduction to Sports Medicine and Athletic Training PowerPoint Presentation by Gary Cannell.
Assessment Chapter Copyright 2004 by Delmar Learning, a division of Thomson Learning, Inc. Assessment Assessment is the first step in the nursing.
ASCO Presentation Summary: Chemotherapy Treatment Plan and Summary Templates as a Component of Comprehensive Cancer Care Kansas Cancer Partnership University.
TEMPLE UNIVERSITY KORNBERG SCHOOL OF DENTISTRY 1 Evidence-based Dental Practice Developing guidelines or clinical recommendations.
The EPEC-O Curriculum is produced by the EPEC TM Project with major funding provided by NCI, with supplemental funding provided by the Lance Armstrong.
RHS 303. TRANSITION OF THEORY AND TREATMENT nature of existence and gives meaning to and guides the action Philosophical Base: Philosophy of occupational.
Dementia NICE quality standard August What this presentation covers Background to quality standards Publication partners Dementia quality standard.
Prostate Cancer Coalition of NC A statewide collaborative effort by concerned organizations and individuals to support awareness, early detection, and.
L1:Apply the concepts of health and wellness to identify health behaviours and factors influencing choice and change in health using an holistic approach.
Canadian Best Practice Recommendations for Stroke Care Recommendation 1: Public Awareness and Patient Education (Updated 2008)
The Interface between Primary Care and Specialty Care in Primary Treatment of Cancer Jonathan Sussman Supportive Cancer Care Research Unit Laura-Mae Baldwin.
Provider Initiated HIV Counseling and Testing Unit 2: Introduction and Rational for PIHCT.
Depression in adults with a chronic physical health problem Implementing NICE guidance 2009 NICE clinical guideline 91.
Richard T. Lee, MD Assistant Professor Medical Director, Integrative Medicine Program March 4, 2011.
Adjuvant Endocrine Therapy for Women with Hormone Receptor- Positive Breast Cancer Clinical Practice Guideline Update.
Cancer-Related Fatigue. Objective The learner will be able to discuss the nursing management of cancer-related fatigue.
©American Society of Clinical Oncology All rights reserved. Antiemetics: American.
Role of Health Care Providers or Sports Medicine Team Members.
Schizophrenia Implementing NICE guidance 2009 NICE clinical guideline 82.
Evidence-Based Public Health Nancy Allee, MLS, MPH University of Michigan November 6, 2004.
The Management of People at High Risk of CVD Dr Richard Healicon Mel Varvel NHS Improvement.
Participation Requirements for a Guideline Panel Co-Chair.
Screening, Assessment, and Care of Anxiety and Depressive Symptoms in Adults with Cancer: An American Society of Clinical Oncology Guideline Adaptation.
PAIN ASSESSMENT PURPOSE To provide guidelines for the appropriate identification and assessment of patients who may experience pain.
© 2017 SlidePlayer.com Inc. All rights reserved.